Related Experiment Video
Updated: Jan 21, 2026

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
Published on: August 21, 2013
3-Chloroplumbagin Induces Cell Death in Breast Cancer Cells Through MAPK-Mediated Mcl-1 Inhibition
Anna Kawiak1, Anna Domachowska1, Aleksandra Krolicka1
1Department of Biotechnology, Intercollegiate Faculty of Biotechnology UG and MUG, University of Gdansk, Gdansk, Poland.
Abstract:
Resistance acquired toward anti-cancer agents is a significant drawback in breast cancer therapy. A key factor contributing to drug resistance is apoptosis suppression associated with the upregulation of anti-apoptotic Bcl-2 family proteins. Specifically, the anti-apoptotic Mcl-1 protein has been shown to play a significant role in drug resistance, making it an important therapeutic target. The present study aimed at determining the antiproliferative activity of 3-chloroplumbagin (ChPL), a naphthoquinone derived from a Dionaea sp., toward breast cancer cells and examining the involvement of Mcl-1 inhibition in ChPL-induced cell death. The results showed that ChPL inhibited breast cancer cell proliferation and induced apoptosis through the intrinsic pathway through down-regulation of anti-apoptotic Bcl-2 family proteins. The induction of apoptosis by ChPL was found to be mediated through MAP kinase signaling inhibition. ChPL inhibited the phosphorylation of MEK and ERK proteins in breast cancer cells, and increased apoptosis induction in cells with reduced ERK expression. Furthermore, ERK silencing decreased the expression of Mcl-1 in ChPL-treated cells. The results of this research indicate that ChPL induces apoptosis in breast cancer cells through MAPK-mediated Mcl-1 inhibition, suggesting further research into its potential in breast cancer treatment.
Insights
3-chloroplumbagin (ChPL) combats breast cancer by inhibiting cell proliferation and inducing apoptosis. This natural compound targets the anti-apoptotic Mcl-1 protein via the MAPK signaling pathway, offering a potential new therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Acquired resistance to anti-cancer drugs is a major challenge in breast cancer treatment.
- Apoptosis suppression, often due to upregulated anti-apoptotic Bcl-2 family proteins like Mcl-1, contributes significantly to drug resistance.
- Mcl-1 is a key therapeutic target for overcoming drug resistance in breast cancer.
Purpose of the Study:
- To evaluate the antiproliferative effects of 3-chloroplumbagin (ChPL) on breast cancer cells.
- To investigate the role of Mcl-1 inhibition in ChPL-induced apoptosis.
- To elucidate the signaling pathways involved in ChPL's anti-cancer activity.
Main Methods:
- Assessed antiproliferative activity of ChPL on breast cancer cell lines.
- Investigated ChPL's effect on apoptosis induction and the intrinsic pathway.
- Examined the involvement of Bcl-2 family proteins, specifically Mcl-1.
- Analyzed the role of Mitogen-Activated Protein (MAP) kinase signaling, including MEK and ERK phosphorylation.
- Utilized ERK silencing to assess its impact on ChPL-induced apoptosis and Mcl-1 expression.
Main Results:
- ChPL demonstrated significant antiproliferative activity against breast cancer cells.
- ChPL induced apoptosis via the intrinsic pathway, accompanied by downregulation of anti-apoptotic Bcl-2 proteins.
- Apoptosis induction by ChPL was mediated by the inhibition of MAP kinase signaling, specifically MEK and ERK phosphorylation.
- Reduced ERK expression enhanced ChPL-induced apoptosis, and ERK silencing led to decreased Mcl-1 expression in ChPL-treated cells.
Conclusions:
- ChPL induces apoptosis in breast cancer cells through MAP kinase-mediated inhibition of Mcl-1.
- These findings highlight ChPL's potential as a therapeutic agent for breast cancer, particularly in overcoming Mcl-1-driven drug resistance.
- Further research is warranted to explore ChPL's clinical applicability in breast cancer treatment.
Related Concept Videos
Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
MAPK Signaling Cascades
Induced Pluripotent Stem Cells
Cell-mediated Immune Responses
Feedback Inhibition

